

A
Box SeqJULY 16 / 2001
S. U. S. P. T. O.Please type a plus sign (+) inside this box →

07-26-01

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53 (b))

Attorney Docket No.	38-21(51862)B
First Inventor	Dotson, Stanton B.
Title	A Method For Assessing Transgene Expression and Copy Number
Express Mail Label No.	EK089244602US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

1. Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)

2. Applicant claims small entity status.

3. Specification [Total Pages 48]
(preferred arrangement set forth below)

- Descriptive title of the invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R and D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings *(if filed)*
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

4. Drawing(s) (35 USC 113) [Total Sheets]

5. Oath or Declaration [Total Pages 3]

a. Newly executed (original or copy)

b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)

i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

6. Application Data Sheet. See 37 CFR 1.76

ADDRESS TO:
 Assistant Commissioner for Patents
 Box Patent Application
 Washington, DC 20231

7. CD-ROM or CD-R in duplicate, large table or Computer Program *(Appendix)*

8. Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all necessary)*

a. Computer Readable Form (CRF)

b. Specification Sequence Listing on:

- i. CD-ROM or CD-R (2 copies); or
- ii. Paper

c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet -document(s))

10. 37 CFR 3.73(b) Statement Power of Attorney *(when there is an assignee)*

11. English Translation Document *(if applicable)*

12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations

13. Preliminary Amendment

14. Return Receipt Postcard (MPEP 503) *(should be specifically itemized)*

15. Certified Copy of Priority Document (s) *(if foreign priority is claimed)*

16. Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.

17. Other: _____

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76:

 Continuation Divisional Continuation-in-part (CIP)

of prior application No.:

Prior Application Information: Examiner:

Group/Art Unit:

For CONTINUATION OR DIVISIONAL APPS ONLY: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

19. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label	<input type="checkbox"/> Insert Customer No. or attach Bar Code		or	<input checked="" type="checkbox"/> Correspondence address below
Name	Lawrence M. Lavin, Jr.			
	Patent Department, E2NA; Monsanto Company			
Address	800 N. Lindbergh Boulevard			
City	St. Louis	State	Missouri	ZIP CODE
Country	USA	Telephone	(314) 694-3602	FAX
Name (Print/Type)	Lawrence M. Lavin, Jr.	Registration No. (Attorney/Agent)	30768	
Signature			Date:	7/25/01

Burden Hour Statement: This form is estimated to take 2 hours to complete. Time will vary depending on the needs of the individual cases. Any comments on the amount of time you required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

JC997 U.S. PTO
09/912968

07/25/01

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2001

Patent fee are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$ 9332)

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Dotson, Stanton B.
Examiner Name	
Group Art Unit	
Attorney Docket No.	38-21(51862)B

METHOD OF PAYMENT (check one)

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number **13-4125**

Deposit Account Name _____

 Charge Any Additional Fee Required under 37 CFR 1.16 and 1.17 Applicant claims small entity status.
See 37 CFR 1.27

3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	0
127	50	227	25	Surcharge - late provisional filing fee or cover she	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex part reexamination	
112	920*	112	1,840*	Requesting publication of SIR prior to Examiner action	0
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	0
115	110	215	55	Extension for reply within first month	0
116	380	216	190	Extension for reply within second month	0
117	870	217	435	Extension for reply within third month	0
118	1,360	218	680	Extension for reply within fourth month	0
128	1,850	228	925	Extension for reply within fifth month	0
119	300	219	150	Notice of Appeal	0
120	300	220	150	Filing a brief in support of an appeal	0
121	260	221	150	Request for Oral hearing	0
138	1,510	138	1,510	Petition to institute a public use proceeding	0
140	110	240	55	Petition to revive - unavoidable	0
141	1,210	241	605	Petition to revive - unintentional	0
142	1,210	242	605	Utility issue fee (or reissue)	0
143	430	243	215	Design issue fee	0
144	430	243	215	Plant issue fee	0
122	130	122	130	Petitions to commissioner	0
123	50	123	50	Processing under 37 CFR 1.17(q)	0
126	240	126	240	Submission of information Disclosure Statement	0
581	40	581	40	Recording each patent assignment per property (times number of properties)	0
146	690	246	345	Filing a submission after final rejection (37 CFR §1.129(a))	0
149	690	249	345	For each additional invention to be examined (37 CFR §1.129(b))	0
179	690	279	345	Request for continued Examination (RCE)	0
169	900	169	900	Request for expedited examination of a design application	0
Other fee (specify) _____					
*Reduced by Basic Filing Fee Paid					SUBTOTAL (3) (\$ 0)


2. EXTRA CLAIM FEES

		Fee from		
Total Claims	34	-20** =	14	X 18 = 252
Independent Claims	3	- 3** =	0	X 80 = 0
Multiple Dependent			270	= 8370

** or number previously paid, if greater; For reissues, see below

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee description
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claims, if not paid
109	80	209	40	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2) (\$ 8622)				

** or number previously paid, if greater; For reissues, see above

SUBMITTED BY		Complete (if applicable)		
Name (Print/Type)	Lawrence M. Lavin, Jr.	Registration No. (Attorney/Agent)	30768	Telephone (314) 694-3602
Signature			Date:	7/25/01

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

Burden Hour Statement. This form is estimated to take 2 hours to complete. Time will vary depending on the needs of the individual cases. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Docket No. 38-21(51862)B
Inventor: Stanton B. Dotson *et al.*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Stanton B. Dotson *et al.*

Appln. No.: To Be Assigned

Filed:

For: A Method For Assessing Transgene
Expression and Copy Number


Art Unit: To Be Assigned

Examiner: To Be Assigned

Atty. Docket: 38-21(51862)B

I hereby verify this transmittal together with the patent application referred to below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 Express Mail Label No. EK089244602US on the date indicated and is addressed to:
Commissioner for Patents, Washington, D.C. 20231

Lawrence M. Lavin, Jr. Registration No. 30,768



Date: 7/25/01

TRANSMITTAL OF NON-PROVISIONAL PATENT APPLICATION

Commissioner for Patents
Washington, D.C. 20231

Box Patent Application

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is the complete patent application of :

A Method For Assessing Transgene Expression And Copy Number

Inventors: John C. Anderson

Stanton B. Dotson

Jon J. Schmuke

The following documents are forwarded herewith for appropriate action by the U.S.
Patent and Trademark Office:

1. This Transmittal Letter;
2. Utility Patent Application Transmittal (PTO/SB/05);
3. Form PTO/SB/17 (in duplicate);
4. U.S. Utility Patent Application entitled:

A Method for Assessing Transgene Expression and Copy Number

and naming as inventors:


John C. ANDERSON, Stanton B. DOTSON, and Jon J. SCHMUKE

the application consisting of:

- a. A specification containing:
 - (i) 40 pages of a description prior to the claims;
 - (ii) 7 pages of claims (34 claims); and
 - (iii) a one (1) page abstract;
5. The computer readable form (CRF) containing the sequence listing information;
6. 2 CD-Rs (Copy 1, Copy 2) containing the Sequence listing;
7. Combined Declaration and Power of Attorney, executed by inventors John C. Anderson, Stanton B. Dotson, and Jon J. Schmuke (3 pages);
8. Statement Regarding Sequence Submission;
9. Form PTO/SB/35
10. Two (2) return postcards.

It is respectfully requested that the attached prepaid postcard be stamped with the filing date and unofficial application number and returned as soon as possible.

Respectfully submitted,



Lawrence M. Lavin, Jr., Esq (Reg. No. 30,768)

Enclosures

Date:

7/28/01

Patent Department, E2NA
Monsanto Company
800 N. Lindbergh Boulevard
St. Louis, MO 63167
Tel: 636-694-3602
Fax: 636-694-1671

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST AND CERTIFICATION
UNDER
35 U.S.C. 122(b)(2)(B)(i)**

First Named Inventor	Stanton B. Dotson
Title	A Method For Assessing Transgene Expression and Copy Number
Attorney Docket No.	38-21(51862)B

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

7/25/01
Date

Signature

LAWRENCE M. LAVIN JR

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Stanton B. Dotson et al

Appln. No.: To Be Assigned

Filed:

For: A Method For Assessing
Transgene Expression and Copy
Number

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 38-21(51862)B

Statement Regarding Sequence Submission


Assistant Commissioner for Patents
Washington, DC 20231

Box Patent Application

Sir:

In accordance with 37 C.F.R. § 1.821(f), the sequence listing information recorded in computer readable form (CRF) submitted herewith in the above-mentioned application is identical to the written sequence listing on CD-R (2 copies).

Respectfully submitted,


Lawrence M. Lavin
(Reg. No. 30,768)

Date: 7/25/01

Patent Department, E2NA, Monsanto Company
800 N. Lindbergh Blvd.
St. Louis, MO 63167

Tel:

FAX: